Subtitle:
Comprehensive medulloblastoma pathology review covering morphology, immunohistochemistry, WHO 2021 molecular classification, risk groups, and exam‑oriented MCQs.

Author: PathologyMCQ Editorial Team

Category: Neuropathology – CNS Tumors

Last Updated: March 2026

Read Time: 18–22 minutes

This is a medical, educational, exam-oriented pathology review focused on diagnosis and histopathology, with emphasis on medulloblastoma pathology for students and residents.

At‑a‑Glance Box

• Medulloblastoma is a malignant embryonal tumor of the cerebellum with distinct histologic and molecular subgroups.
• Integrated reporting combines morphology, medulloblastoma immunohistochemistry, and molecular testing as per WHO 2021 classification.
• Specific patterns such as MBEN and large cell/anaplastic correlate with SHH activation and high‑risk biology, respectively.

Difficulty level: Moderate–Difficult (postgraduate neuropathology level).

Table of Contents

What is medulloblastoma pathology as per WHO 2021?

Medulloblastoma pathology describes a malignant, embryonal, primary central nervous system tumor arising in the cerebellum and defined by integrated histologic and molecular features in the WHO 2021 classification.

Medulloblastoma accounts for the majority of malignant pediatric posterior fossa tumors and is characterized by densely cellular sheets of undifferentiated neuroepithelial cells. It shows a propensity for cerebrospinal fluid dissemination and is therefore staged using neuraxis imaging and CSF cytology at diagnosis. WHO 2021 emphasizes that the diagnostic label now combines histologic pattern (classic, desmoplastic/nodular, large cell/anaplastic, MBEN) with molecular group (WNT‑activated, SHH‑activated TP53‑wildtype, SHH‑activated TP53‑mutant, non‑WNT/non‑SHH).

How is classic medulloblastoma histology described?

Classic medulloblastoma histology shows diffuse sheets of small blue round cells with hyperchromatic nuclei, scant cytoplasm, and frequent mitoses and apoptoses, sometimes forming Homer Wright rosettes.

On H&E, the tumor is highly cellular, composed of monotonous round to oval nuclei with finely granular chromatin, inconspicuous nucleoli, and a high nuclear‑to‑cytoplasmic ratio. Necrosis and apoptotic bodies are common, reflecting the high proliferative rate quantified by Ki‑67 or MIB‑1 labeling indices often exceeding 30–40%. Neuroblastic differentiation is indicated by Homer Wright rosettes, defined as circular arrangements of tumor cells surrounding central fibrillary neuropil rather than a true lumen.

The stroma in classic medulloblastoma pathology is usually delicate, with thin‑walled vessels and minimal desmoplasia. Tumor cells typically infiltrate the cerebellar cortex and may form a plaque‑like growth pattern along the leptomeninges, explaining the risk of subarachnoid dissemination. Recognition of this baseline pattern is essential because additional features such as nodularity or anaplasia modify risk assessment and suggest specific molecular groups.

What are the major histologic variants in medulloblastoma pathology?

The major histologic variants in medulloblastoma pathology are desmoplastic/nodular, medulloblastoma with extensive nodularity (MBEN), and large cell/anaplastic (LC/A) medulloblastoma, each with distinct architecture and clinical relevance.

How is desmoplastic/nodular medulloblastoma defined?

Desmoplastic/nodular medulloblastoma displays nodules of pale, more differentiated cells separated by densely reticulin‑rich internodular zones of proliferating tumor cells.

Nodules appear pale on H&E due to reduced nuclear density and contain neurocytic cells often showing neuronal differentiation. The surrounding internodular areas are highly cellular, rich in reticulin fibers on special staining, and harbor the bulk of mitotically active tumor cells. This variant is strongly associated with SHH‑activated medulloblastoma and often occurs in infants and young children.

What characterizes medulloblastoma with extensive nodularity (MBEN)?

MBEN is characterized by large, confluent reticulin‑free pale nodules occupying most of the tumor, creating a “grapelike” or micronodular appearance with markedly diminished proliferation within nodules.

MBEN almost exclusively belongs to the SHH‑activated infant subgroup and shows very low Ki‑67 indices within the nodules compared with higher proliferation in residual internodular zones. Recognition is important because infants with MBEN/SHH tumors have relatively favorable outcomes when treated with reduced‑intensity regimens avoiding or minimizing craniospinal irradiation.

How is large cell/anaplastic medulloblastoma defined?

Large cell/anaplastic medulloblastoma demonstrates marked nuclear pleomorphism, cell enlargement, nuclear molding, prominent nucleoli, and frequent apoptotic bodies with geographic necrosis, often associated with high metastatic potential.

Cells in LC/A medulloblastoma are larger with vesicular chromatin, distinct nucleoli, and frequent mitoses and apoptoses resulting in a “starry sky” pattern. Anaplasia includes features such as nuclear molding, cell wrapping, and multilayered rosettes, and is often admixed with classic areas, so diagnosis requires assessing whether these features are significant or predominant. LC/A histology correlates with MYC amplification, increased risk of metastasis, and inferior survival, prompting classification as high‑risk even in the absence of other adverse factors.

How does immunohistochemistry support medulloblastoma diagnosis and subtyping?

Immunohistochemistry (IHC) in medulloblastoma pathology confirms neuronal differentiation, helps exclude histologic mimics, measures proliferation, and serves as a surrogate for molecular subgrouping when comprehensive genomics is not available.

Which markers demonstrate neuronal and glial differentiation?

Neuronal differentiation in medulloblastoma pathology is demonstrated by diffuse cytoplasmic positivity for synaptophysin and variable nuclear or cytoplasmic NeuN expression, whereas GFAP is negative or only focally positive and helps exclude high‑grade glioma. Synaptophysin highlights neuropil within Homer Wright rosettes and diffuse tumor cell cytoplasm, supporting embryonal neuronal phenotype. NeuN labeling is more variable but favors neuronal differentiation and is often reduced in anaplastic regions. GFAP positivity, when present, is usually limited to reactive astrocytes or rare tumor cells and must not be interpreted as evidence of diffuse glioma.

How is proliferation index assessed in medulloblastoma pathology?

Ki‑67 (MIB‑1) is used to quantify proliferation in medulloblastoma pathology, typically showing high labeling indices in classic and LC/A tumors but relatively low indices within MBEN nodules.

High Ki‑67 supports a diagnosis of a high‑grade embryonal tumor rather than a low‑grade neuronal neoplasm. In MBEN, Ki‑67 is distinctly low or absent within pale nodules but elevated in narrow internodular zones, explaining the favorable outcome when appropriately stratified. Reporting the proliferation index is useful for prognostication and for comparing pre‑ and post‑treatment specimens.

Which IHC markers serve as molecular surrogates for medulloblastoma subgroups?

A small panel including β‑catenin, YAP1, GAB1 (or p75NGFR), and OTX2 can classify medulloblastoma into WNT‑activated, SHH‑activated, and non‑WNT/non‑SHH groups with reasonable accuracy, forming an important component of medulloblastoma immunohistochemistry in routine practice.

• WNT‑activated tumors show strong nuclear β‑catenin and are typically YAP1 positive and GAB1 negative.​
• SHH‑activated tumors are YAP1 positive and GAB1 positive, usually with cytoplasmic or membranous β‑catenin but not nuclear accumulation.
• Non‑WNT/non‑SHH tumors are negative for YAP1 and GAB1 and lack nuclear β‑catenin, often retaining strong OTX2 expression.

Additional markers such as p53 immunostaining assist in sub‑stratifying SHH tumors into TP53‑mutant (diffuse strong p53) and TP53‑wildtype (scattered weak nuclear staining) categories. INI1 and LIN28A are retained or negative respectively in typical medulloblastoma and are primarily used to rule out atypical teratoid/rhabdoid tumor (ATRT) and embryonal tumor with multilayered rosettes (ETMR).

Summary table – core IHC in medulloblastoma pathology

How is WHO 2021 molecular classification applied in medulloblastoma pathology?

WHO 2021 classification integrates histology, medulloblastoma immunohistochemistry, and molecular testing to assign tumors to WNT‑activated, SHH‑activated TP53‑wildtype, SHH‑activated TP53‑mutant, and non‑WNT/non‑SHH molecular groups with specific prognostic implications.

WNT‑activated medulloblastomas constitute about 10% of cases, often arise in older children or adolescents, and show classic histology with excellent prognosis when non‑metastatic. SHH‑activated medulloblastomas comprise roughly 30%, occur in infants and adults, frequently exhibit desmoplastic/nodular or MBEN histology, and require further division into TP53‑wildtype and TP53‑mutant entities because TP53 mutation identifies a very high‑risk subgroup. Non‑WNT/non‑SHH tumors, including groups 3 and 4, form the remaining majority; they often have classic or LC/A morphology and intermediate to poor outcomes depending on additional clinical and genetic factors such as MYC amplification or metastatic disease.

In practice, an integrated diagnosis format is recommended, listing: (1) histologic type, (2) molecular group, and (3) essential molecular alterations. An example is “Medulloblastoma, SHH‑activated, TP53‑wildtype, desmoplastic/nodular histology, CNS WHO grade 4”. This standardized terminology ensures alignment with clinical trial risk‑stratification schemes and allows uniform communication between pathologists, oncologists, and researchers.

What are subgroup‑specific morphologic clues and risk correlations?

Certain morphologic patterns and ancillary findings in medulloblastoma pathology correlate with molecular subgroup and clinical risk, guiding initial impression and treatment decisions even before full profiling is available.

What clues suggest SHH‑activated MBEN with favorable risk?

Large, reticulin‑free nodules with low Ki‑67 labeling within nodules, particularly in infants, strongly suggest SHH‑activated MBEN, which is associated with favorable biology if recognized early and treated appropriately. Radiologically, these tumors often arise in cerebellar hemispheres rather than the midline vermis, supporting SHH activation. Early recognition allows de‑escalated therapy protocols that minimize neurocognitive sequelae from craniospinal irradiation.

What features indicate high‑risk large cell/anaplastic disease?

Marked cytologic atypia, large cell morphology with prominent nucleoli, nuclear molding, and extremely high Ki‑67 accompanied by diffuse anaplasia indicate LC/A medulloblastoma, which shows high metastatic potential and poorer survival. These tumors often belong to group 3 or SHH‑TP53‑mutant categories and may harbor MYC or MYCN amplification, further defining very high‑risk patients who benefit from intensified multimodal therapy and enrollment in high‑risk protocols.

How is practical integration of H&E, IHC, and molecular testing performed?

A practical workflow begins with H&E morphology to raise suspicion of medulloblastoma and to identify specific patterns such as desmoplasia, nodularity, or anaplasia, followed by an IHC panel that narrows the likely molecular group, and finally targeted or genome‑wide molecular profiling to confirm subgroup and key genetic alterations.

WHO 2021 emphasizes that morphology alone cannot define medulloblastoma entities; instead, it provides supportive context that must be integrated with IHC and molecular findings to issue a final diagnosis. This approach is particularly important in low‑resource settings where surrogate IHC panels allow reasonably accurate subgroup assignment when comprehensive genomic testing is unavailable.

High – yield MCQS

quiz_id = 587

Exam pearl and key takeaway in medulloblastoma pathology

Exam Pearl: Nuclear β‑catenin positivity on IHC in a cerebellar small blue cell tumor is the most useful single clue for WNT‑activated medulloblastoma, which carries an excellent prognosis in non‑metastatic cases.

Key Takeaway: Modern medulloblastoma pathology requires an integrated approach combining morphology, a targeted immunohistochemistry panel, and molecular profiling to accurately assign WHO 2021 groups and guide risk‑adapted therapy.

Continue learning medulloblastoma pathology

Ready to Master This Topic?